Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label study. Arthritis & Rheumatology. 2026.
From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis. Arthritis Care and Research. 2026.
2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2026; 78(7):1361-1386.
2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis Care and Research. 2026; 78(7):815-839.
Validation of the Pediatric Arthritis Ultrasound Scoring System for the Elbow, Wrist, and Finger Joints in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2026; 78(7):905-913.
The Renal Activity Index for Lupus Identifies Active Renal Disease and Treatment Response in Adult Patients With Systemic Lupus Erythematosus and Lupus Nephritis. Arthritis Care and Research. 2026; 78(6):723-732.
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial. Arthritis Care and Research. 2026; 78(6):761-770.
Cumulative Social Disadvantage and Disease Activity in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study. Arthritis Care and Research. 2026.
Soluble factors released from fibroblast-like synoviocytes of JIA patients with future extended course can condition persistent JIA synovial fibroblasts for increased IL-6 production. Arthritis Research & Therapy. 2026; 28(1).
Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial. Arthritis & Rheumatology. 2026; 78(3):752-762.
The Renal Activity Index for Lupus: Validation for Prediction of Kidney Inflammation in Adult Patients With Lupus Nephritis. Journal of Rheumatology. 2026; 53(3):283-291.
Reliability and Construct Validity of the Physician's Global Assessment of Lung Disease in Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. ACR Open Rheumatology. 2026; 8(3):e90006.
CAR T-cell therapy and indications for pediatric rheumatology: Structured overview of applications, risks, and considerations. Best Practice and Research: Clinical Rheumatology. 2026; 40(1):102143.
399 Biopsychosocial Risk Influences on Development and Generation of Early-onset Pain: The BRIDGE Pain Study Protocol. Journal of Pain. 2026; 41:106046.
Facilitating Expedited Drug Approval-the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease. Arthritis Care and Research. 2026.
Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS). Rheumatology and Therapy. 2026; 13(1):265-278.
Characterization of TNF-Alpha Inhibitor Induced Paradoxical Psoriasiform Dermatitis at a Single Center via Retrospective Chart Review. Pediatric Dermatology. 2026; 43(1):84-87.
Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting. Journal of Rheumatology. 2026; 53(1):85-94.
Differences in time to drug initiation and inactive disease achievement by insurance type in patients with nonsystemic juvenile idiopathic arthritis. Drugs and Therapy Perspectives. 2026; 42(1):203-210.
Cognitive Behavioral Therapy for Youth With Childhood-Onset Lupus: A Randomized Clinical Trial. Arthritis Care and Research. 2025.
Navigating the Biosimilars from Bench to Bedside in Juvenile Idiopathic Arthritis. Paediatric Drugs. 2025; 27(6):679-691.
Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week phase II study. Lupus Science and Medicine. 2025; 12(2).
Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry. Pediatric Rheumatology. 2025; 23(1):105.
Three-Year Outcomes and Latent Class Trajectory Analysis of the Childhood Arthritis and Rheumatology Research Alliance Polyarticular JIA Consensus Treatment Plans Study. Arthritis & Rheumatology. 2025; 77(10):1433-1441.
Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial. ACR Open Rheumatology. 2025; 7(10):e70097.
Interdisciplinary Clinical Practice Guidelines for patient-centred management of juvenile-onset systemic lupus erythematosus. EULAR Rheumatol Open. 2025; 1(4):380-393.
2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Care and Research. 2025; 77(9):1045-1065.
Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial. Journal of Rheumatology. 2025; 52(9):919-926.
2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis & Rheumatology. 2025; 77(9):1115-1135.
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force. Annals of the Rheumatic Diseases. 2025; 84(8):1425-1436.
Disease activity at two consecutive registry visits and subsequent medication escalation for patients with juvenile idiopathic arthritis in the CARRA registry. Pediatric Rheumatology. 2025; 23(1):77.
Utility of patient-reported outcomes for pulmonary symptoms and sleep disturbance and impairment in children with systemic juvenile idiopathic arthritis. Pediatric Rheumatology. 2025; 23(1):74.
Volumetric Absorptive Microsampling Combined with Mass Spectrometry to Support Pharmacokinetically-Guided Precision Dosing of Mycophenolate Mofetil in Pediatric Lupus Nephritis Patients. Journal of Applied Laboratory Medicine. 2025; 10(4):806-819.
Development and Validation of Multiplex Assays for Lupus Nephritis Activity Biomarkers. Kidney International Reports. 2025; 10(7):2255-2264.
ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. The Lancet Rheumatology. 2025; 7(7):e505-e518.
Infections preceding diagnosis associated with myositis phenotypes in a national patient registry. Clinical and Experimental Rheumatology. 2025; 43(7):1204-1212.
POS1400 PERIVENTRICULAR ABNORMALITY GRADIENTS OF RELAXOMETRY AND SUSCEPTIBILITY METRICS BY NEUROIMAGING: COMPARING LUPUS AND MULTIPLE SCLEROSIS. Annals of the Rheumatic Diseases. 2025; 84:1421-1422.
POS1172 EVALUATING THE STANDARDIZED STEROID REGIMEN (SSR) FOR CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: RETROSPECTIVE INSIGHTS FROM REAL-WORLD DATA. Annals of the Rheumatic Diseases. 2025; 84:1242-1243.
POS0841 THE RENAL ACTIVITY INDEX FOR LUPUS IDENTIFIES AND PREDICTS COMPLETE RENAL REMISSION OR ABSENCE OF KIDNEY INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 2025; 84:985-986.
POS0295 RELATIONSHIP AMONG A PEDIATRIC-SPECIFIC ULTRASOUND SCORING SYSTEM FOR THE EVALUATION OF ARTHRITIS AND BIOLOGIC MARKERS OF INFLAMMATION. Annals of the Rheumatic Diseases. 2025; 84:556.
OP0212 EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. Annals of the Rheumatic Diseases. 2025; 84:176-177.
VOLUME AND DYNAMIC BLOOD FLOW OF THE CHOROID PLEXUS IN NEUROINFLAMMATORY DISEASE. Journal of Rheumatology. 2025; 52(Suppl 1):106-107.
INTERNATIONAL EFFORT IN HARMONIZING COGNITIVE IMPAIRMENT RESEARCH IN SYSTEMIC LUPUS ERYTHEMATOSUS. Journal of Rheumatology. 2025; 52(Suppl 1):39-40.
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study. Lupus Science and Medicine. 2025; 12(1).
Candidate Tear-Based Uveitis Biomarkers in Children with JIA Based on Arthritis Activity and Topical Corticosteroid Use. Ocular Immunology and Inflammation. 2025; 33(4):603-612.
Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase 1 Trial. Arthritis Care and Research. 2025; 77(5):584-593.
Clinical, Immunologic, and Genetic Characteristics in Patients With Syndrome of Undifferentiated Recurrent Fevers. Arthritis & Rheumatology. 2025; 77(5):596-605.
25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges. Arthritis Care and Research. 2025; 77(5):573-583.
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction. Arthritis Care and Research. 2025; 77(4):513-521.
Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis. Clinical Rheumatology. 2025; 44(3):901-922.
Development of CARRA/PReS-endorsed consensus Core and Expanded Datasets in childhood-onset systemic lupus erythematosus for international registry-based research. Annals of the Rheumatic Diseases. 2025; 84(2):158-168.
Comparative Effectiveness and Safety of the JAK Inhibitors and Biologic Disease-Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta-Analysis of Randomized Controlled Trials. ACR Open Rheumatology. 2025; 7(2):e11788.
Implementation of the Lupus Low Disease Activity State in Pediatric Rheumatology Care: The Role of the Visual Analog Scale. ACR Open Rheumatology. 2025; 7(1):e11737.
Racial Disparities and Achievement of the Low Lupus Disease Activity State: A CARRA Registry Study. Arthritis Care and Research. 2025; 77(1):38-49.
Occupational and Hobby Exposures Associated With Myositis Phenotypes in a National Myositis Patient Registry. Arthritis Care and Research. 2025; 77(1):104-115.
Achieving Medication-Free Remission in Patients With Juvenile Dermatomyositis. ACR Open Rheumatology. 2025; 7(1):e11751.
Effect of an Electronic Pill Bottle on Hydroxychloroquine Adherence in Pediatric Lupus: Results of a Novel Direct-to-Family Pilot Trial. ACR Open Rheumatology. 2025; 7(1):e11780.
New medicines for childhood-onset systemic lupus erythematosus: an EU perspective on paediatric drug development. Frontiers in Medicine. 2025; 12:1583140.
41 Systemic lupus erythematosus in childhood and adolescence. In: Dubois' Lupus Erythematosus and Related Syndromes. Elsevier; 2025:580-595.
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76(12):1723-1732.
Validation of the ankle-specific pediatric arthritis ultrasound scoring system in children with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism. 2024; 69:152545.
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study. Journal of Rheumatology. 2024; 51(11):1125-1134.
Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses. Journal of Allergy and Clinical Immunology: In Practice. 2024; 12(11):2996-3013.e7.
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Annals of the Rheumatic Diseases. 2024; 83(11):1561-1571.
Development of CARRA/PReS-endorsed consensus Core and Expanded Datasets in childhood-onset systemic lupus erythematosus for international registry-based research. Annals of the Rheumatic Diseases. 2024.
Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Pediatric Rheumatology. 2024; 22(1):88.
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology. 2024; 63(SI2):SI195-SI206.
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis. Rheumatology. 2024; 63(9):2535-2546.
Renal disease in pediatric rheumatology. Current Opinion in Rheumatology. 2024; 36(5):322-327.
Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76(8):1090-1098.
Revisiting Childhood-Onset Systemic Lupus Erythematosus. Turkish Archives of Pediatrics. 2024; 59(4):336-344.
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research & Therapy. 2024; 26(1):125.
AB0982 DOMAINS FOR INCLUSION IN A NOVEL TREATMENT RESPONSE MEASURE FOR SYSTEMIC LUPUS ERYTHEMATOSUS (TRM-SLE): RESULTS OF A MODIFIED DELPHI STUDY. Annals of the Rheumatic Diseases. 2024; 83:1805-1807.
Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature. Arthritis & Rheumatology. 2024; 76(3):455-468.
Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium held February 13-14, 2022. Pediatric Rheumatology. 2024; 21(Suppl 1):91.
The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. Pediatric Rheumatology. 2024; 21(Suppl 1):150.
Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study). Journal of Clinical Trials. 2024; 14(4).
Systemic lupus erythematosus in childhood and adolescence. In: Dubois Lupus Erythematosus and Related Syndromes. 2024:580-595.
Digital health technology to support patient-centered shared decision making at point of care for juvenile idiopathic arthritis. Frontiers in Pediatrics. 2024; 12:1457538.
Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept. Arthritis Care and Research. 2023; 75(11):2259-2266.
Health Equity Implications of Missing Data Among Youths With Childhood-Onset Systemic Lupus Erythematosus: A Proof-of-Concept Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75(11):2285-2294.
Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials. Journal of Rheumatology. 2023; 50(11):1471-1480.
Practice Analysis and Determining the Knowledge and Skills Expected of a Pediatric Rheumatologist. ACR Open Rheumatology. 2023; 5(11):619-623.
Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design. Arthritis & Rheumatology. 2023; 75(10):1856-1866.
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce. Nature reviews. Rheumatology. 2023; 19(9):592-602.
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. The Lancet. 2023; 402(10401):555-570.
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study. Arthritis Care and Research. 2023; 75(8):1804-1814.
Urine biomarker score captures response to induction therapy with lupus nephritis. Pediatric Nephrology. 2023; 38(8):2679-2688.
Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry. Journal of Rheumatology. 2023; 50(8):1047-1057.
Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care and Research. 2023; 75(7):1553-1562.
Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Science and Medicine. 2023; 10(2).
POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL. Annals of the Rheumatic Diseases. 2023; 82:379-380.
POS1140 A NOVEL TLR7/8 ANTAGONIST BLOCKS PRO-INFLAMMATORY FUNCTION OF IMMUNE COMPLEXES FROM LUPUS PATIENTS AND ABROGATES LUPUS-LIKE DISEASE IN MICE. Annals of the Rheumatic Diseases. 2023; 82:899.
Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy. Cell Reports Medicine. 2023; 4(5):101036.
Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research. 2023; 75(5):998-1006.
Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. Pediatric Nephrology. 2023; 38(5):1653-1665.
Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE. Lupus Science and Medicine. 2023; 10(1).
Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75(4):715-723.
Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry. Rheumatology. 2023; 62(2):804-814.
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Annals of the Rheumatic Diseases. 2023; 82(1):154-160.
Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Journal of Rheumatology. 2023; 50(1):98-106.
Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2023; 41(1):186-194.
Systemic Lupus Erythematosus. In: A Clinician's Pearls & Myths in Rheumatology. Springer Nature; 2023:167-212.
Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. American Journal of Ophthalmology. 2022; 244:183-195.
Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology. 2022; 20(1):107.
Stability of Novel Urinary Biomarkers Used for Lupus Nephritis. Journal of the American Society of Nephrology. 2022; 33(11S):961-962.
Treatment Guidelines in Pediatric Rheumatic Diseases. Rheumatic Disease Clinics of North America. 2022; 48(3):725-746.
Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry. Pediatric Rheumatology. 2022; 20(1):50.
Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis. Arthritis Care and Research. 2022; 74(7):1058-1064.
Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Annals of the Rheumatic Diseases. 2022; 81(7):990-997.
POS0340 PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. Annals of the Rheumatic Diseases. 2022; 81:422-423.
OP0221 EFFICACY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA) Annals of the Rheumatic Diseases. 2022; 81:145-146.
LB0002 BARICITINIB IN JUVENILE IDIOPATHIC ARTHRITIS: A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, WITHDRAWAL, EFFICACY AND SAFETY STUDY. Annals of the Rheumatic Diseases. 2022; 81:207-208.
Tofacitinib for juvenile idiopathic arthritis - Authors' reply. The Lancet. 2022; 399(10338):1866.
Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus. Lupus Science and Medicine. 2022; 9(1).
Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology. 2022; 20(1):18.
International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis & Rheumatology. 2022; 74(2):263-273.
Biomarkers in Childhood-Onset Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America. 2022; 48(1):271-285.
Juvenile idiopathic arthritis. Springer Nature; 2022:5.
Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis. Lupus. 2022; 31(1):97-104.
The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry. Frontiers in Medicine. 2022; 9:842586.
Stability of novel urinary biomarkers used for lupus nephritis. Frontiers in Pediatrics. 2022; 10:974049.
Cross-cultural adaptation and initial validation of the Brazilian-Portuguese version of the pediatric automated neuropsychological assessment metrics. Frontiers in Psychology. 2022; 13:945425.